8-K: Certara Reports Mixed Q2 2024 Results: Software Growth Offsets Services Decline

Certara's second quarter results show strong software revenue growth of 13% but a 3% decline in services revenue, leading to a net loss of $12.6 million.

Summary

• Certara reported its financial results for the second quarter of 2024, showing a mixed performance.
• Total revenue reached $93.3 million, a 3% increase compared to $90.5 million in the same quarter of 2023.
• Software revenue grew significantly by 13% to $38.2 million, up from $33.7 million in the prior year.
• However, services revenue declined by 3% to $55.1 million, compared to $56.7 million in the second quarter of 2023.
• The company experienced a net loss of $12.6 million, a significant drop from a net income of $4.7 million in the second quarter of 2023.
• Adjusted EBITDA decreased to $26.3 million, down from $32.4 million in the same period last year.
• Total bookings increased by 15% to $98.9 million, with software bookings up 17% and services bookings up 14%.
• Operating expenses increased by $21.4 million to $62.5 million due to investments in innovation, growth, and M&A activities.
• The company is reiterating its full-year 2024 revenue guidance of $385 million to $400 million.
• Adjusted EBITDA margin is expected to be between 31% and 33% for the full year.
• Adjusted diluted earnings per share are projected to be in the range of $0.41 to $0.46 for the full year.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results. While software growth is positive, the decline in services revenue and the net loss are concerning. The reiteration of full-year guidance provides some stability, but the overall performance is not overwhelmingly positive.

Positives

• Software revenue experienced a significant growth of 13% year-over-year.
• Total bookings increased by 15%, indicating strong future revenue potential.
• Software bookings grew by 17%, demonstrating high demand for their software products.
• The company is reiterating its full-year 2024 financial guidance, showing confidence in their outlook.
• Certara is expanding its biosimulation portfolio with the acquisition of Chemaxon.

Negatives

• Services revenue declined by 3% year-over-year, indicating a slowdown in that segment.
• The company reported a net loss of $12.6 million, a significant decrease from the net income of $4.7 million in the same quarter last year.
• Adjusted EBITDA decreased by $6.1 million compared to the second quarter of 2023.
• Operating expenses increased significantly by $21.4 million due to investments in innovation and M&A.
• Adjusted net income decreased by $7.0 million compared to the second quarter of 2023.

Risks

• The company faces risks related to competition within its market.
• There is a risk of deceleration in the acceptance of model-informed biopharmaceutical discovery.
• Changes or delays in government regulations could impact the business.
• Increasing competition and cost pressures within the pharmaceutical and biotechnology industries pose a risk.
• Economic conditions, including inflation and recession, could affect the company's performance.
• Delays or cancellations in projects due to supply chain issues or clinical trial delays could impact revenue.
• The company faces risks related to its ability to integrate acquisitions successfully.
• There are risks associated with the use of artificial intelligence and machine learning in their products and services.
• The company's ability to meet obligations under indebtedness and have sufficient capital to operate is a risk.
• Disruptions in the operations of third-party providers who host their software solutions could impact service delivery.

Future Outlook

Certara is reiterating its full-year 2024 guidance, expecting revenue between $385 million and $400 million, adjusted EBITDA margin between 31% and 33%, and adjusted diluted earnings per share between $0.41 and $0.46.

Management Comments

• Certara's financial results were driven by strong performance in software and by improved biotech customer activity, offset by slowing demand in large biopharma customers in services, said William F. Feehery, Chief Executive Officer.
• Achieving our 2024 financial targets remains the key priority while also focusing investment on our software platforms including integrating AI across our portfolio, said John Gallagher, Chief Financial Officer.

Industry Context

The results reflect a broader trend in the biopharmaceutical industry where software and technology solutions are gaining importance, while traditional service models may face headwinds. The acquisition of Chemaxon indicates a strategic move to capitalize on the growing biosimulation market.

Comparison to Industry Standards

• Certara's 13% software revenue growth is strong compared to some traditional CROs (Contract Research Organizations) that may be experiencing slower growth in their service divisions.
• Companies like Simulations Plus (SLP) and Schrodinger (SDGR) are also focused on software solutions for drug discovery and development, and Certara's growth in this area positions them well against these competitors.
• The decline in services revenue is a concern, as many CROs are seeing growth in this area, suggesting Certara may need to adjust its strategy in this segment.
• The decrease in net income and adjusted EBITDA is a negative trend compared to industry benchmarks, where many companies are focused on profitability and margin expansion.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased profitability.
• Employees may be impacted by the company's focus on software and potential shifts in the services division.
• Customers may benefit from the company's focus on innovation and new product launches.
• Suppliers may see changes in demand based on the company's performance in different segments.
• Creditors may be concerned about the company's profitability and ability to meet debt obligations.

Next Steps

• Certara will host a conference call on August 6, 2024, to discuss the second quarter 2024 financial results.
• The company will continue to focus on integrating AI across its software portfolio.
• Certara will proceed with the acquisition of Chemaxon to expand its biosimulation capabilities.

Key Dates

Keywords

biosimulation, software, drug development, pharmaceutical, biotech, revenue, EBITDA, bookings, financial results, AI